BACKGROUNDTriple-damaging breast most cancers (TNBC) is highly aggressive with an elevated metastatic incidence as compared to other breast cancer subtypes. However, as a result of absence of clinically reliable biomarkers and specific therapy in TNBC, results are suboptimal. Consequently, there is